Document registry — page 17
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
Moderate08 Apr 2026 -
Consultation on the draft monograph for Ecnoglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over 40 weeks. The Institute holds no reported primary result for this…
03 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Apr 2026 -
Consultation on the draft monograph for Thymosin beta-4, which the assessment committee released for public comment before ratification. The draft grades the compound's…
29 Mar 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: What is the effect of reconstitution practice on the dose actually delivered…
27 Mar 2026 -
Consultation on the draft monograph for retatrutide, a triple agonist at the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon…
25 Mar 2026 -
Consultation on the draft of this network meta-analysis, which registers the question: In adults with obesity, does a multi-receptor incretin agonist produce a larger…
23 Mar 2026 -
Do incretin-based therapies increase the incidence of acute pancreatitis?
Moderate22 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low22 Mar 2026 -
Consultation on the draft methodological review of transitivity in the incretin network. The review examines whether the trials connecting these interventions through…
20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
20 Mar 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over 76 weeks. The Institute holds no reported primary result for this record and…
19 Mar 2026 -
Single-arm open-label, phase 3 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low19 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low19 Mar 2026 -
Record of documents ratified in the 2026 Q1 assessment cycle.
18 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Orforglipron in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
18 Mar 2026 -
Single-arm open-label, phase 3 study of Retatrutide in sleep apnoea over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low18 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Mar 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low16 Mar 2026 -
In the population defined for obesity and overweight in adults, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the…
Moderate13 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over 68 weeks or longer. The Institute holds no reported…
13 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low13 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its…
High11 Mar 2026 -
In the population defined for cutaneous wound healing and tissue repair, is the effect of Thymosin beta-4 maintained across the full duration of the contributing trials?
Low10 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low10 Mar 2026 -
In adults who have lost weight during treatment with an incretin receptor agonist, what happens to body weight after treatment is withdrawn?
Moderate09 Mar 2026 -
Research peptides with a declared GLP-1 specialty, SARMs and injectable oils. Factory-direct model.
09 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, is the effect of CJC-1295 maintained across the full duration of…
Low07 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over 52 weeks. The Institute holds no reported primary result for…
06 Mar 2026 -
Consultation on the draft monograph for Melanotan-II, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Mar 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over 68 weeks or longer. The Institute holds no reported…
03 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low03 Mar 2026 -
Randomised crossover, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low03 Mar 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate02 Mar 2026
page 17 of 41